Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection: Foster City, California Friday, June 20, 2025, 1 ...

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move ...

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

The US Food and Drug Administration (FDA) has approved use of the vaccine Yeztugo, manufactured by Gilead Sciences, is an anti-HIV drug.

The Food and Drug Administration has approved a highly effective new HIV prevention medication, known as Yeztugo. In clinical ...

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

The United States Food and Drug Administration (FDA) has approved a twice-a-year drug to be used to prevent HIV.

The US Food and Drug Administration (FDA) on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents at high risk of ...

The United States Food and Drug Administration, FDA, has approved a new long-acting injectable drug, Lenacapavir, for the ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

Lenacapavir, the world's first twice-yearly HIV prevention shot, gets US FDA nod-offering a discreet, long-acting solution ...

The US FDA has approved lenacapavir, a biannual injection by Gilead, to prevent HIV, potentially revolutionizing the fight against the epidemic.